MCID: MNC007
MIFTS: 52

Monocytic Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 55 15 72
M5b Acute Differentiated Monocytic Leukemia 72
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD9CM 35 206.8
ICD10 33 C93 C93.9
UMLS 72 C0153903 C0598894 C1318544

Summaries for Monocytic Leukemia

Disease Ontology : 12 A myeloid leukemia that is characterized by a dominance of monocytes in the marrow.

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to leukemia, acute monocytic and acute monoblastic leukemia. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Mesna and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cardiovascular system

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 415)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 34.5 KMT2A KIAA0100 KAT6A CD14
2 acute monoblastic leukemia 32.2 KMT2A IL6 CXCL8 CSF2
3 hematopoietic stem cell transplantation 30.4 TNF IL6 IFNG
4 langerhans cell histiocytosis 29.9 IFNG CSF2 CSF1
5 neuritis 29.7 TNF IL1B IFNG
6 purpura 29.7 TNF IL6 F3
7 graft-versus-host disease 29.6 TNF IL6 IL1B IFNG
8 pertussis 29.6 TNF ITGAM IL6 IL1B
9 leukemia, acute myeloid 29.5 TNF KMT2A KAT6A ITGAM CSF2 CASP3
10 obstructive jaundice 29.4 TNF IL6 CXCL8
11 autoimmune disease 29.4 TNF IL6 IL1B IFNG
12 endocarditis 29.4 TNF IL6 CXCL8
13 visceral leishmaniasis 29.3 TNF IFNG CXCL8
14 leishmaniasis 29.2 TNF ITGAM IL1B IFNG
15 thrombocytosis 29.1 IL6 F3 CSF2
16 central nervous system disease 29.1 TNF IL6 IL1B IFNG CASP3
17 acute respiratory distress syndrome 29.0 TNF IL6 IL1B CXCL8
18 respiratory failure 29.0 TNF F3 CXCL8
19 aspergillosis 29.0 TNF IFNG CSF2
20 crohn's colitis 29.0 TNF IL1B IFNG CXCL8
21 hematologic cancer 28.9 KMT2A CSF2 CSF1 CASP3
22 cytomegalovirus infection 28.9 TNF IL6 IL1B CXCL8 CASP3
23 aplastic anemia 28.7 TNF IL6 IFNG CSF2 CSF1
24 sarcoidosis 1 28.7 TNF IL1B IFNG CSF2
25 meningitis 28.6 TNF IL6 IL1B IFNG CXCL8
26 toxic shock syndrome 28.6 TNF IL6 IL1B IFNG CXCL8
27 inflammatory bowel disease 28.5 TNF IL6 IL1B IFNG CXCL8
28 myelodysplastic syndrome 28.5 TNF KMT2A ITGAM EGR1 CSF2 CSF1
29 myeloma, multiple 28.4 TNF IL6 CXCL8 CSF2 CASP3
30 nervous system disease 27.9 TNF IL6 IL1B IFNG CSF2 CASP3
31 adult acute monocytic leukemia 12.8
32 aleukemic monocytic leukemia cutis 12.6
33 chronic monocytic leukemia 12.5
34 subacute monocytic leukemia 12.5
35 leukemia 11.0
36 myeloid leukemia 10.5
37 acute leukemia 10.5
38 scorpion envenomation 10.5 TNF IL6
39 fixed drug eruption 10.4 IFNG CASP3
40 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 TNF IL6
41 chromosomal triplication 10.4
42 lymphocytic leukemia 10.3
43 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.3
44 chronic myelomonocytic leukemia 10.3
45 histiocytosis 10.3
46 mycobacterium chelonae 10.3 CXCL8 CD14
47 intermediate uveitis 10.2 TNF IL6 IFNG
48 mycoplasma pneumoniae pneumonia 10.2 TNF IL6 IFNG
49 posterior uveitis 10.2 TNF IL6 IFNG
50 congenital cytomegalovirus 10.2 TNF PPARG IL1B

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 CAB39L CASP3 CSF1 CSF2 EGR1 F3
2 hematopoietic system MP:0005397 10.4 CAB39L CASP3 CD14 CSF1 CSF2 EGR1
3 homeostasis/metabolism MP:0005376 10.36 CASP3 CD14 CSF1 CSF2 EGR1 F3
4 cellular MP:0005384 10.35 CASP3 CSF1 CSF2 EGR1 F3 IFNG
5 growth/size/body region MP:0005378 10.35 CASP3 CD14 CSF1 CSF2 EGR1 F3
6 immune system MP:0005387 10.34 CASP3 CD14 CSF1 CSF2 EGR1 F3
7 behavior/neurological MP:0005386 10.33 CASP3 CSF1 CSF2 EGR1 F3 IFNG
8 integument MP:0010771 10.26 CASP3 CSF1 CSF2 EGR1 F3 IFNG
9 mortality/aging MP:0010768 10.25 CASP3 CD14 CSF1 CSF2 EGR1 F3
10 endocrine/exocrine gland MP:0005379 10.2 CASP3 CSF1 CSF2 EGR1 IFNG IL6
11 craniofacial MP:0005382 10.17 CASP3 CSF1 CSF2 IFNG IL1B KAT6A
12 embryo MP:0005380 10.16 CSF2 EGR1 F3 IFNG KAT6A KMT2A
13 nervous system MP:0003631 10.13 CASP3 CSF1 CSF2 EGR1 F3 IFNG
14 liver/biliary system MP:0005370 10.06 CSF1 EGR1 IFNG IL6 KAT6A KMT2A
15 neoplasm MP:0002006 10.02 CSF2 EGR1 F3 IFNG IL1B IL6
16 muscle MP:0005369 10.01 CASP3 CSF1 F3 IFNG IL6 KMT2A
17 reproductive system MP:0005389 9.96 CASP3 CSF1 CSF2 EGR1 IFNG IL6
18 respiratory system MP:0005388 9.81 CASP3 CD14 CSF1 CSF2 EGR1 F3
19 skeleton MP:0005390 9.73 CASP3 CD14 CSF1 CSF2 EGR1 IFNG
20 vision/eye MP:0005391 9.23 CASP3 CSF1 EGR1 F3 IFNG IL6

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Idarubicin Approved Phase 3 58957-92-9 42890
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
leucovorin Approved Phase 3 58-05-9 143 6006
10
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
11
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
12
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
13
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
14
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
15
Melphalan Approved Phase 3 148-82-3 460612 4053
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Carmustine Approved, Investigational Phase 3 154-93-8 2578
18
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
19
Hydroxyurea Approved Phase 3 127-07-1 3657
20
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
23
Daunorubicin Approved Phase 3 20830-81-3 30323
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
27
Histamine Approved, Investigational Phase 3 51-45-6 774
28
Cyproheptadine Approved Phase 3 129-03-3 2913
29
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31 Lintuzumab Investigational Phase 3 166089-32-3
32
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
33 Staurosporine Experimental Phase 3 62996-74-1
34 Vaccines Phase 3
35 Antibodies Phase 3
36 Antibodies, Monoclonal Phase 3
37 Immunoglobulins Phase 3
38 Gemtuzumab Phase 3
39 Antineoplastic Agents, Immunological Phase 3
40 Alkylating Agents Phase 2, Phase 3
41 Antirheumatic Agents Phase 3
42 Antineoplastic Agents, Alkylating Phase 2, Phase 3
43 Antineoplastic Agents, Phytogenic Phase 3
44 Adjuvants, Immunologic Phase 3
45 Etoposide phosphate Phase 3
46 Analgesics Phase 3
47 Protective Agents Phase 3
48 Radiation-Protective Agents Phase 3
49 Nucleic Acid Synthesis Inhibitors Phase 3
50 Folic Acid Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
6 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
10 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
11 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
12 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
13 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
14 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
15 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
16 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
17 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
18 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
19 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
20 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
22 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
23 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
24 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
25 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
26 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
27 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
28 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
29 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
30 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
31 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
32 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
33 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
34 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
35 Pilot Study of Sodium Phenylbutyrate Plus Azacytidine Completed NCT00006019 Phase 2 azacitidine;sodium phenylbutyrate
36 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
37 A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00005801 Phase 2
38 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
39 A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) Completed NCT00049179 Phase 2 cytarabine;gemtuzumab ozogamicin
40 Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study Completed NCT00003178 Phase 2 cladribine;idarubicin
41 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
42 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
43 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
44 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
45 Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study Completed NCT00006122 Phase 2 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
46 A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed NCT00005962 Phase 2 cyclophosphamide;cytarabine;gemtuzumab ozogamicin;liposomal daunorubicin citrate;topotecan hydrochloride
47 A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 Completed NCT00005793 Phase 1, Phase 2 Cytarabine;Daunorubicin;Etoposide;Topotecan
48 A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older Completed NCT00004217 Phase 2 cytarabine;daunorubicin hydrochloride;valspodar
49 Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin "7+3" Regimen Completed NCT00004215 Phase 2 cytarabine;daunorubicin hydrochloride
50 A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen Completed NCT00070135 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

41
Monocytes, Myeloid, Bone, Bone Marrow, Endothelial, Skin, T Cells

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 1915)
# Title Authors PMID Year
1
Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. 9 38
20427734 2010
2
The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. 9 38
20438701 2010
3
Effect of Sargassum thunbergii on ROS mediated oxidative damage and identification of polyunsaturated fatty acid components. 9 38
20171254 2010
4
A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. 9 38
19506293 2009
5
Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-alpha through an ERK1/2-dependent pathway. 9 38
19556303 2009
6
Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells. 9 38
19333701 2009
7
Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-kappaB pathways. 9 38
19218821 2009
8
Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. 9 38
17870167 2008
9
A new simple multi-well plate-based assay for monocyte differentiation using human monocytic leukemia THP-1 cells. 9 38
17920620 2007
10
MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. 9 38
17694082 2007
11
LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22). 9 38
17532767 2007
12
Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. 9 38
17409565 2007
13
Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy. 9 38
17239427 2007
14
Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. 9 38
17139107 2006
15
Rolling and adhesion of apoptotic monocytes is impaired by loss of functional cell surface-expressed P-selectin glycoprotein ligand-1. 9 38
16839361 2006
16
ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. 9 38
16426569 2006
17
[Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration]. 9 38
16584580 2006
18
Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells. 9 38
16497166 2006
19
[In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells]. 9 38
16552959 2005
20
MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia. 9 38
16111539 2005
21
Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. 9 38
15984600 2005
22
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. 9 38
15767555 2005
23
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. 9 38
15680279 2005
24
Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. 9 38
15016631 2004
25
Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. 9 38
15313893 2004
26
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. 9 38
12738674 2003
27
A synergistic increase of apoptosis utilizing Fas antigen expression induced by low doses of anticancer drug. 9 38
13677932 2003
28
Regulation of A + U-rich element-directed mRNA turnover involving reversible phosphorylation of AUF1. 9 38
12819195 2003
29
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. 9 38
12761814 2003
30
Differential effect of Bcl-xl over-expression on cell death of the monocytic leukemia cell line U937. 9 38
12553012 2002
31
MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. 9 38
11965546 2002
32
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. 9 38
11861382 2002
33
PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. 9 38
11861425 2002
34
Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells. 9 38
11734301 2002
35
Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. 9 38
11781384 2002
36
Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon gamma. 9 38
11739196 2001
37
Histamine increases the expression of LOX-1 via H2 receptor in human monocytic THP-1 cells. 9 38
11728449 2001
38
Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque. 9 38
11689197 2001
39
Apoptosis induction by epigallocatechin gallate involves its binding to Fas. 9 38
11478767 2001
40
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. 9 38
11243405 2001
41
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). 9 38
10824998 2000
42
Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 9 38
10784404 2000
43
Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. 9 38
10639586 2000
44
Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. 9 38
11426586 2000
45
Role of CD14 expression in the differentiation-apoptosis switch in human monocytic leukemia cells treated with 1alpha,25-dihydroxyvitamin D3 or dexamethasone in the presence of transforming growth factor beta1. 9 38
10547074 1999
46
Cytokine response of human macrophage-like cells after contact with polyethylene and pure titanium particles. 9 38
10537260 1999
47
Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. 9 38
10497217 1999
48
THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells. 9 38
10573130 1999
49
CD14 expression and production by human hepatocytes. 9 38
10488701 1999
50
9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. 9 38
10479651 1999

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF ITGAM IL6 IL1B IFNG EGR1
2
Show member pathways
13.73 TNF IL6 IL1B IFNG CXCL8 CSF2
3
Show member pathways
13.47 TNF ITGAM IL6 IL1B CXCL8 CSF2
4
Show member pathways
13.45 TNF ITGAM IL6 IL1B IFNG EGR1
5
Show member pathways
13.37 TNF MYH7B IL6 IL1B CXCL8 CSF2
6
Show member pathways
13.15 TNF IL6 IL1B IFNG CXCL8 CD14
7
Show member pathways
13.01 TNF IL6 IL1B CXCL8 CSF2 CASP3
8
Show member pathways
12.94 TNF IL6 IL1B IFNG CXCL8 CASP3
9
Show member pathways
12.9 PPARG ITGAM CSF2 CD14 CASP3
10 12.87 PPARG IL6 IFNG CXCL8 CASP3
11
Show member pathways
12.85 TNF IL6 IL1B IFNG CXCL8 CD14
12 12.81 TNF IL1B CSF1 CD14 CASP3
13
Show member pathways
12.65 TNF IL6 IL1B IFNG CD14
14
Show member pathways
12.65 TNF IL6 IL1B IFNG CSF2
15
Show member pathways
12.46 TNF IL6 IL1B IFNG CXCL8 CSF2
16
Show member pathways
12.44 TNF IL6 IL1B IFNG CXCL8 CD14
17
Show member pathways
12.43 TNF IL6 IL1B IFNG CSF1
18 12.39 TNF IL6 EGR1 CSF2
19 12.39 PPARG KMT2A ITGAM IL6 CXCL8 CSF2
20
Show member pathways
12.37 TNF IL6 IL1B IFNG EGR1 CXCL8
22
Show member pathways
12.36 TNF ITGAM IL1B IFNG CASP3
23 12.36 TNF ITGAM IL6 IL1B IFNG CD14
24
Show member pathways
12.33 TNF IL6 IL1B F3 CXCL8
25
Show member pathways
12.32 TNF IL6 CXCL8 CD14
26
Show member pathways
12.32 TNF IL6 IL1B IFNG CXCL8 CD14
27 12.3 TNF IL6 IL1B EGR1 CXCL8 CASP3
28 12.25 TNF IL6 IFNG CASP3
29 12.17 TNF PPARG IL1B IFNG CSF1
30
Show member pathways
12.17 TNF ITGAM IL6 IL1B IFNG CSF2
31
Show member pathways
12.13 TNF IL6 IL1B IFNG
32 12.13 TNF IL6 IL1B IFNG EGR1 CXCL8
33 12.12 TNF IL6 IL1B CSF2 CSF1 CASP3
34 12.11 TNF ITGAM IL6 IL1B CXCL8
35 12.1 TNF ITGAM IL6 IFNG CSF2 CSF1
36 12.08 KMT2A IL6 IL1B IFNG CXCL8
37 12.01 TNF IL1B CXCL8 CD14
38 12 TNF IL6 IL1B F3 EGR1 CXCL8
39
Show member pathways
11.97 IL6 CXCL8 CSF2 CD14
40 11.96 TNF ITGAM IL6 IL1B CSF2 CSF1
41 11.95 IL6 IL1B IFNG CXCL8 CSF2 CD14
42 11.94 IL6 IFNG EGR1 CXCL8 CSF2
43 11.92 TNF IL6 IL1B IFNG CXCL8 CSF2
44 11.89 TNF ITGAM IL1B IFNG
45 11.88 TNF PPARG IL6 IL1B IFNG CSF2
46 11.81 TNF IL6 IL1B CXCL8 CSF2
47
Show member pathways
11.81 TNF IL6 IL1B IFNG CXCL8 CSF2
48 11.79 TNF ITGAM IL6 IL1B CXCL8 CD14
49
Show member pathways
11.75 TNF PPARG IFNG EGR1 CXCL8 CSF2
50 11.74 IL6 CXCL8 CASP3

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF KIAA0100 IL6 IL1B IFNG F3
2 membrane raft GO:0045121 9.56 TNF ITGAM CD14 CASP3
3 extracellular space GO:0005615 9.32 TNF ITGAM IL6 IL1B IFNG F3
4 MOZ/MORF histone acetyltransferase complex GO:0070776 9.16 KAT6B KAT6A

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 TNF IL6 IL1B CXCL8 CSF1 CD14
2 positive regulation of gene expression GO:0010628 9.91 TNF IL6 IL1B IFNG EGR1 CSF2
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TNF PPARG IL6 IL1B
4 response to organic substance GO:0010033 9.86 TNF PPARG CASP3
5 positive regulation of transcription, DNA-templated GO:0045893 9.86 TNF PPARG KMT2A KAT6B KAT6A IL6
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL6 IFNG CSF2
7 cellular response to organic cyclic compound GO:0071407 9.84 TNF IL1B CASP3
8 regulation of insulin secretion GO:0050796 9.84 TNF IL1B IFNG
9 apoptotic signaling pathway GO:0097190 9.83 TNF CD14 CASP3
10 positive regulation of interleukin-6 production GO:0032755 9.83 TNF IL6 IL1B
11 humoral immune response GO:0006959 9.82 TNF IL6 IFNG
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TNF IL1B CD14
13 positive regulation of interferon-gamma production GO:0032729 9.8 TNF IL1B CD14
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF IL1B IFNG
15 cellular response to organic substance GO:0071310 9.78 IL1B EGR1 CASP3
16 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.77 TNF IL1B CSF2
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TNF IL1B CD14
18 negative regulation of neurogenesis GO:0050768 9.72 TNF IL6 IL1B
19 positive regulation of osteoclast differentiation GO:0045672 9.7 TNF IFNG CSF1
20 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.69 TNF PPARG F3
21 response to molecule of bacterial origin GO:0002237 9.68 CXCL8 CD14
22 positive regulation of podosome assembly GO:0071803 9.68 TNF CSF2
23 negative regulation of lipid storage GO:0010888 9.67 TNF IL6
24 positive regulation of glial cell proliferation GO:0060252 9.67 TNF IL6 IL1B
25 regulation of establishment of endothelial barrier GO:1903140 9.65 TNF IL1B
26 positive regulation of interleukin-23 production GO:0032747 9.64 IFNG CSF2
27 positive regulation of fever generation GO:0031622 9.63 TNF IL1B
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 TNF IL1B IFNG
29 cellular response to lipopolysaccharide GO:0071222 9.63 TNF IL6 IL1B CXCL8 CSF2 CD14
30 sequestering of triglyceride GO:0030730 9.62 TNF IL1B
31 response to glucocorticoid GO:0051384 9.61 TNF IL6 CASP3
32 positive regulation of chemokine biosynthetic process GO:0045080 9.58 TNF IL1B EGR1
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.56 TNF IFNG
34 positive regulation of neuroinflammatory response GO:0150078 9.5 TNF IL6 IL1B
35 positive regulation of phagocytosis, engulfment GO:0060100 9.37 PPARG
36 chronic inflammatory response to antigenic stimulus GO:0002439 9.31 TNF
37 cytokine-mediated signaling pathway GO:0019221 9.28 TNF ITGAM IL6 IL1B F3 CXCL8
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.13 TNF IL1B IFNG
39 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TNF PPARG KMT2A KAT6B KAT6A IL6
40 positive regulation of cell proliferation GO:0008284 10.08 IL6 IL1B IFNG CSF2 CSF1
41 negative regulation of transcription, DNA-templated GO:0045892 10.07 TNF PPARG KAT6B KAT6A IFNG CSF2
42 immune response GO:0006955 10.04 TNF IL6 IL1B IFNG CXCL8 CSF2

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TNF PPARG MYH7B KMT2A KAT6B KAT6A
2 transcription regulatory region DNA binding GO:0044212 9.56 TNF PPARG KMT2A EGR1
3 protease binding GO:0002020 9.5 TNF F3 CASP3
4 cytokine activity GO:0005125 9.17 TNF IL6 IL1B IFNG CXCL8 CSF2
5 H4 histone acetyltransferase activity GO:0010485 9.16 KAT6B KAT6A

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....